Catalyst

Slingshot members are tracking this event:

Cardiff Oncology's (CRDF) Phase 1b/2 data of Onvansertib, Folfiri and Avastin (bevacizumab) in KRAS-Mutated Colorectal Cancer to be Presented at AACR April 10, 2021

Source Link:
https://www.prnewswire.com/news-releases/cardiff-oncology-announces-upcoming-presentations-at-the-aacr-annual-meeting-2021-301244979.html

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
CRDF
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Apr 12, 2021
Occurred Source:
https://cardiffoncology.investorroom.com/2021-04-12-Cardiff-Oncology-Announces-Onvansertib-Phase-1b-2-Data-that-Continues-to-Demonstrate-Robust-Response-to-Treatment-and-Progression-Free-Survival-in-KRAS-Mutated-mCRC
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Onvansertib, Folfiri, Avastin, Kras Mutant Metastatic Coloractal Cancer
About Us
Media Center
Connect with Us
© 2025 Slingshot Insights. All rights reserved.